Literature DB >> 1357156

Characterization of [3H]YM617, R-(-)-5-[2-[[2[ethoxyring(n)-3H](o-ethoxyphenoxy)ethyl]amino]- propyl]-2-methoxybenzenesulfonamide HCl, a potent and selective alpha-1 adrenoceptor radioligand.

H Yazawa1, M Takanashi, K Sudoh, O Inagaki, K Honda.   

Abstract

The binding properties of a new radioligand, R(-)-5-[2-[[2[ethoxyring(n)-3H](o- ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide++ + HCl ([3H]YM617), were studied in membranes of the rat hippocampus and spleen. [3H]YM617 rapidly associated with its binding sites in both membranes and reached steady state by 20 min at 25 degrees C. The specific binding of [3H]YM617 appeared to be saturable, and Scatchard analysis revealed a linear plot, suggesting a single population of binding sites with a dissociation constant of 0.170 +/- 0.016 nM (n = 6) in the hippocampus and 0.195 +/- 0.036 (n = 4) in the spleen. The maximal binding sites in the hippocampus and spleen were 203.0 +/- 43.2 (n = 6) and 72.4 +/- 17.0 (n = 4) fmol/mg protein, respectively. Chlorethylclonidine (10(-5) M for 10 min) treatment reduced the Bmax values of [3H]YM617 and [3H]prazosin to a similar degree in the rat hippocampus (10-15%) and spleen (40-50%). Alpha adrenoceptor agonists and antagonists competed with [3H]YM617 for binding sites in the following order: YM617 > prazosin > WB4101 > bunazosin > 5-methylurapidil > S(+)-isomer of YM617 > phentolamine > yohimbine > norepinephrine = phenylephrine > methoxamine in the hippocampus, and prazosin > YM617 > bunazosin > WB4101 > 5-methylurapidil > phentolamine > S(+)-isomer of YM617 > yohimbine > norepinephrine > phenylephrine > methoxamine in the spleen. In the hippocampus, prazosin and bunazosin produced biphasic displacement of [3H]YM617, but not [3H]prazosin binding. In contrast, only monophasic curves were obtained against either radioligand in the spleen.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1357156

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

Review 1.  α1-Adrenoceptors and muscarinic receptors in voiding function - binding characteristics of therapeutic agents in relation to the pharmacokinetics.

Authors:  Shizuo Yamada; Yoshihiko Ito; Hideo Tsukada
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

2.  Oxytocin receptors expressed and coupled to Ca2+ signalling in a human vascular smooth muscle cell line.

Authors:  H Yazawa; A Hirasawa; K Horie; Y Saita; E Iida; K Honda; G Tsujimoto
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

3.  Alpha 1-adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Evidence for heterogeneity of chloroethylclonidine-resistant rat renal alpha 1-adrenoceptor.

Authors:  M C Michel; R Büscher; J Kerker; H Kraneis; W Erdbrügger; O E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-10       Impact factor: 3.000

4.  High-affinity specific [3H]tamsulosin binding to alpha 1-adrenoceptors in human prostates with benign prostatic hypertrophy.

Authors:  S Yamada; C Tanaka; T Ohkura; R Mori; R Kimura; O Inagaki; K Honda; K Kawabe
Journal:  Urol Res       Date:  1994

5.  Functional evidence equating the pharmacologically-defined alpha 1A- and cloned alpha 1C-adrenoceptor: studies in the isolated perfused kidney of rat.

Authors:  D R Blue; D W Bonhaus; A P Ford; J R Pfister; N A Sharif; I A Shieh; R L Vimont; T J Williams; D E Clarke
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

6.  Age-related changes in alpha 1-adrenoceptors in rat prostate.

Authors:  N Moriyama; S Kurimoto; Y Nagase; O Inagaki; M Takanashi; K Kawabe
Journal:  Urol Res       Date:  1995
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.